University College London's National Amyloidosis Center leads a multinational team reporting that a single infusion of an in ...

AAVantgarde receives US FDA orphan drug designation & UK CTA approval for AAVB-039 to treat Stargardt disease: Milan Saturday, October 4, 2025, 17:00 Hrs [IST] AAVantgarde Bio (AA ...

Bayer reinforced its commitment to advancing healthcare solutions for patients in the APAC region with very diverse healthcare landscapes and varying patient needs.'By 2050, heart failure cases in the ...

A BREAKTHROUGH in gene therapy is offering fresh hope. The Wirral branch of the Motor Neurone Disease Association (MNDA) has welcomed the development following the success of a new treatment for ...

The FDA has approved Inluriyo, a first-in-class oral therapy for ESR1-mutated advanced breast cancer, marking a significant ...

Following up on previous, dimly received issuances, a new set of ideas published by the FDA to streamline regulatory pathways ...

The neurodegenerative disease damages patients' motor, cognitive and behavioral controls, which sometimes manifest as ...

In this GEN webinar, an outstanding panel of CGT experts will unpack some of the key themes raised during the recent FDA Listening Session and examine their implications for the future of product ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Novo Nordisk has a factor VIII mimetic in a phase 3 trial, and a Chinese company is forging ahead with its gene therapy ...

AAVB-039 is an intra-retinal AAV8-intein-mediated investigational gene therapy targeting the gene associated with Stargardt ...

Despite SBRT (radiation) to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.